Individualizing prophylaxis in hemophilia: A review

Expert Review of Hematology

Volumn 8, Issue 2, 2015, Pages 237-246

  Petrini, Pia ^a   Valentino, Leonard A ^b,c   Gringeri, Alessandro ^d   Re, Wendy M ^e   Ewenstein, Bruce ^e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Baxter Bioscience   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d BAXTER INNOVATIONS GMBH   (Austria)

^e BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

arthropathy; hemarthroses; hemophilia; personalized medicine; pharmacokinetics; prophylaxis

Indexed keywords

ADOLESCENT DISEASE; ARTHROPATHY; BLEEDING TENDENCY; CHEMOPROPHYLAXIS; CHILDHOOD DISEASE; CLINICAL EVALUATION; CLINICAL STUDY; DISEASE COURSE; HEMARTHROSIS; HEMOPHILIA; HUMAN; JOINT FUNCTION; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; PHARMACODYNAMICS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; HEMOPHILIA A;

HEMARTHROSIS; HEMOPHILIA A; HUMANS; INDIVIDUALIZED MEDICINE;

EID: 84924419773     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2015.1002465     Document Type: Review

References (65)

1. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia 2013;19:e1-e47
2. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357:535-44
3. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965;(suppl 77): 3-132
4. Nilsson IM, Berntorp E, Lofqvist T, et al. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992;232:25-32
5. Feldman BM, Pai M, Rivard GE, et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006;4:1228-36
6. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010;363:301-4
7. Trusheim MR, Burgess B, Hu SX, et al. Quantifying factors for the success of stratified medicine. Nat Rev Drug Discov 2011;10:817-33
8. Astermark J, Petrini P, Tengborn L, et al. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999;105: 1109-13
9. Petrini P. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B? Haemophilia 2001;7: 99-102
10. Street A. Developing models of haemophilia care. Haemophilia 2012;18(Suppl 4):89-93
11. Björkman S, Blanchette VS, Fischer K, et al. Comparative pharmacokinetics of plasma-and albumin-free recombinant factor VIII in children and adults: The influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost 2010;8:730-6
12. Collins PW, Blanchette VS, Fischer K, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009;7: 413-20
13. Geraghty S, Dunkley T, Harrington C, et al. Practice patterns in haemophilia A therapy-global progress towards optimal care. Haemophilia 2006;12:75-81
14. Gissel M, Whelihan MF, Ferris LA, et al. The influence of prophylactic factor VIII in severe haemophilia A. Haemophilia 2011;18:193-9
15. Valentino LA. Controversies regarding the prophylactic management of adults with severe haemophilia A. Haemophilia 2009;15:5-18, quiz 9-22
16. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994;236:391-9
17. Fischer K, Astermark J, van der Bom JG, et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 2002;8:753-60
18. Funk MB, Schmidt H, Becker S, et al. Modified magnetic resonance imaging score compared with orthopaedic and radiological scores for the evaluation of haemophilic arthropathy. Haemophilia 2002;8:98-103
19. Ravanbod R, Torkaman G, Esteki A. Biotribological and biomechanical changes after experimental haemarthrosis in the rabbit knee. Haemophilia 2011;17:124-33
20. Valentino LA, Hakobyan N, Kazarian T, et al. Experimental haemophilic synovitis: rationale and development of a murine model of human factor VIII deficiency. Haemophilia 2004;10:280-7
21. Valentino LA, Hakobyan N, Kazarian T, et al. Prevention of haemarthrosis in a murine model of acute joint bleeding. Haemophilia 2008;15:314-19
22. van den Berg WB. Lessons from animal models of arthritis over the past decade. Arthritis Res Ther 2009;11:250
23. Roosendaal G, TeKoppele JM, Vianen ME, et al. Blood-induced joint damage: A canine in vivo study. Arthritis Rheum 1999;42: 1033-9
24. Sabatino DE, Nichols TC, Merricks E, et al. Animal models of hemophilia. Prog Mol Biol Transl Sci 2012;105:151-209
25. Hakobyan N, Enockson C, Cole AA, et al. Experimental haemophilic arthropathy in a mouse model of a massive haemarthrosis: gross, radiological and histological changes. Haemophilia 2008;14:804-9
26. Acharya SS, Kaplan RNM, Macdonald D, et al. Neoangiogenesis contributes to the development of hemophilic synovitis. Blood 2011;117:2484-93
27. Jansen NW, Roosendaal G, Lundin B, et al. The combination of the biomarkers urinary C-terminal telopeptide of type II collagen, serum cartilage oligomeric matrix protein, and serum chondroitin sulfate 846 reflects cartilage damage in hemophilic arthropathy. Arthritis Rheum 2009;60:290-8
28. Gringeri A, Ewenstein B, Reininger A. The burden of bleeding in haemophilia: is one bleed too many? Haemophilia 2014;20: 459-63
29. Schramm W, Gringeri A, Ljung R, et al. Haemophilia care in Europe: The ESCHQoL study. Haemophilia 2012;18: 729-37
30. Kraft J, Blanchette V, Babyn P, et al. Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada. J Thromb Haemost 2012;10: 2494-502
31. Den Uijl IE, Mauser Bunschoten EP, Roosendaal G, et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia 2011;17: 849-53
32. Berntorp E, Spotts G, Patrone L, et al. Advancing personalized care in hemophilia A: Ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method. Biologics 2014;8:115-27
33. Ahnstrom J, Berntorp E, Lindvall K, et al. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004;10:689-97
34. Tarantino MD, Collins PW, Hay CR, et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004;10:428-37
35. Ehrlich HJ, Wong WY, Ewenstein BM, et al. Development of novel treatment options for patients with haemophilia. Hamostaseologie 2013;33(Suppl 1):S36-8
36. Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 2012;119: 3031-7
37. Coyle TE, Reding M, Lin JC, et al. An open-label phase I study to evaluate the pharmacokinetics and safety profile of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII, in previously treated patients with severe hemophilia A. Presented at: World Federation of Hemophilia World Congress; July 8-12, Paris, France; 2012
38. Tiede A, Brand B, Fischer R, et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-man trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost 2013;11:670-8
39. Negrier C, Knobe K, Tiede A, et al. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: A first human dose trial in patients with hemophilia B. Blood 2011;118:2695-701
40. Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013;369:2313-23
41. Saulyte Trakymiene S, Clausen N, Poulsen LH, et al. Progression of haemophilic arthropathy in children: A Lithuanian-Danish comparative study. Haemophilia 2012;19:212-18
42. Gringeri A, Lundin B, Mackensen SV, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011;9:700-10
43. Pollmann H, Klamroth R, Vidovic N, et al. Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: A subgroup analysis of the ADVATE PASS post-approval, non-interventional study. Ann Hematol 2013;92:689-98
44. Ragni MV, Fogarty PJ, Josephson NC, et al. Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres. Haemophilia 2012;18: 63-8
45. Biss TT, Chan AK, Blanchette VS, et al. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia 2008;14: 923-30
46. Hilliard P, Zourikian N, Blanchette V, et al. Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study. J Thromb Haemost 2013;11:460-6
47. Wu R, Luke KH, Poon MC, et al. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: A pilot study in China. Haemophilia 2011;17:70-4
48. Dodd C, Watts RG. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center. Haemophilia 2012;18:561-7
49. Rew L, Horner SD, Brown A. Health-risk behaviors in early adolescence. Issues Compr Pediatr Nurs 2011;34:79-96
50. Duncan N, Shapiro A, Ye X, et al. Treatment patterns, health-related quality of life and adherence to prophylaxis among haemophilia A patients in the United States. Haemophilia 2012;18:760-5
51. De Moerloose P, Urbancik W, Van Den Berg HM, et al. A survey of adherence to haemophilia therapy in six European countries: results and recommendations. Haemophilia 2008;14: 931-8
52. Khair K, Gibson F, Meerabeau L. The benefits of prophylaxis: views of adolescents with severe haemophilia. Haemophilia 2011;18:e286-9
53. Broderick CR, Herbert RD, Latimer J, et al. Association between physical activity and risk of bleeding in children with hemophilia. JAMA 2012;308:1452-9
54. Valentino LA, Forsyth A, Witkop M, et al. Is bleeding in hemophilia really spontaneous or activity related: Analysis of US patient/caregiver data from the Hemophilia Experiences, Results and Opportunities (HERO) study. Presented at: American Society of Hematology Annual Meeting. December 7-10; New Orleans, LA; 2013
55. Walsh CE, Valentino LA. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices. Haemophilia 2009;15:1014-21
56. Collins P, Faradji A, Morfini M, et al. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost 2010;8:83-9
57. Tagliaferri A, Coppola A, Feola G, et al. Impact on healthcare costs and quality of life of secondary prophylaxis in adolescent and adult patients with severe haemophilia A: The POTTER study [abstract PA 1.13-2]. J Thromb Haemost 2013;11:321-2
58. Oldenburg J, Zimmermann R, Katsarou O, et al. A diagnostic, cross-sectional evaluation of joint status using magnetic resonance imaging in patients with severe hemophilia A treated with prophylaxis versus on-demand therapy. Presented at: World Federation of Hemophilia World Congress. July 8-12, Paris, France; 2012
59. Valentino LA, Rusen L, Elezovic I, et al. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia 2014;20:398-406
60. Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012;10:359-67
61. Valentino LA, Reyes CM, Ewenstein B, et al. ADVATE prophylaxis: post hoc analysis of joint bleeding episodes. Haemophilia 2014. [Epub ahead of print]
62. Collins PW, Björkman S, Fischer K, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe haemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2009;8:269-75
63. Lindvall K, Astermark J, Bjorkman S, et al. Daily dosing prophylaxis for haemophilia: A randomized crossover pilot study evaluating feasibility and efficacy. Haemophilia 2012;18:855-9
64. Valentino LA. Considerations in individualizing prophylaxis in patients with haemophilia A. Haemophilia 2014;20: 607-15
65. Franchini M, Mannucci PM. Past, present and future of hemophilia: A narrative review. Orphanet J Rare Dis 2012;7:24